Boundless Bio, Inc.

BOLD SEC CIK 0001782303 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$64.38M
22,747,985 shares Covers every share class this company has on file.
Insiders on file
1
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$1.88M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
2.91%
insider-held value divided by market capitalisation

What Boundless Bio, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
No revenue figure: this company’s filings tag profit, but no single revenue total.
Net income
-$58.20M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
28
Yahoo Finance
Why the revenue box is blank

US GAAP has no one “total revenue” tag that every filer uses. A bank reports interest and dividend income separately from non-interest income; closed-end funds, blank-cheque companies and some property trusts report the same way; and a company that has not sold anything yet — a drug developer still in trials, for instance — files no revenue at all. Adding two differently defined income lines together would produce a number that appears in no filing, so we publish a revenue figure only where the filing tags one annual, US-dollar revenue fact we can point at. A blank here means no such tag, not that we failed to look.

Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Boundless Bio, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

People who file insider reports against Boundless Bio, Inc..
Insider Reported role Shares Value Last action
Jonathan E Lim CEO 653,479 $1.88M C Conversion of derivative Apr 2, 2024 position reported

Recent insider transactions

Of the 7 rows we hold, 0 are open-market purchases and 3 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Boundless Bio, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Jul 1, 2026 Kristina Burow S Open-market sale 16,000 $2.49 $39.8K SEC filing ↗
Jul 1, 2026 Robert Nelsen S Open-market sale 16,000 $2.49 $39.8K SEC filing ↗
Jul 1, 2026 Keith Crandell S Open-market sale 16,000 $2.49 $39.8K SEC filing ↗
Jul 1, 2026 Kristina Burow M Option exercise or conversion 16,000 $1.03 $16.5K SEC filing ↗
Jul 1, 2026 Robert Nelsen M Option exercise or conversion 16,000 $1.03 $16.5K SEC filing ↗
Jul 1, 2026 Keith Crandell M Option exercise or conversion 16,000 $1.03 $16.5K SEC filing ↗
Apr 2, 2024 Jonathan E Lim C Conversion of derivative 525,274 $0.00 $0 SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 12 filers hold a position

Who owns Boundless Bio, Inc.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Do not add these figures together. 11 of the positions below were reported on filings shared by several filers at once.

Why the same shares appear twice

On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.

Filers holding a position in Boundless Bio, Inc.

Funds, trusts and companies that disclose an ownership position in Boundless Bio, Inc..
Owner Reported role Shares Filed
ARCH Venture Fund IX Overage, L.P. TenPercentOwner 1,181,766 joint
ARCH Venture Fund IX, L.P. TenPercentOwner 1,181,766 joint
ARCH Venture Fund X Overage, L.P. TenPercentOwner 1,181,766 joint
ARCH Venture Partners IX Overage, L.P. TenPercentOwner 1,181,766 joint
ARCH Venture Partners IX, L.P. TenPercentOwner 1,181,766 joint
ARCH Venture Partners IX, LLC TenPercentOwner 1,181,766 joint
ARCH Venture Partners X Overage, L.P. TenPercentOwner 1,181,766 joint
ARCH Venture Partners X, LLC TenPercentOwner 1,181,766 joint
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. TenPercentOwner 556,233
RA Capital Healthcare Fund LP Director,Other,TenPercentOwner 295,844 joint
RA CAPITAL MANAGEMENT, L.P. Director,Other,TenPercentOwner 295,844 joint
RA Capital Nexus Fund II, L.P. Director,TenPercentOwner 295,844 joint

See the full ownership map — every entity that files as an owner of a US public company.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Boundless Bio, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Boundless Bio, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.